U.S.-based leading healthcare venture capital fund with unique de-risking concept
Why Us?
A key differentiator of FutureMED is that we help our portfolio companies execute early-stage clinical trials in Kazakhstan. This allows our LPs and portfolio companies to significantly reduce their financial risks.
Central Asian republics (Kazakhstan, Uzbekistan, Kyrgyzstan, Tajikistan) have high levels of health care that are compatible with high-quality clinical trials of new therapies. Kazakhstan in particular was ranked 55th in Johns Hopkins’ Global Health Security Index out of 195 countries worldwide.
These countries have significantly lower costs for clinical trials than what is typically seen in Western and other developed nations.
Clinical trial startup times are significantly faster in Kazakhstan than in other regions due to the lower amount of bureaucracy in these countries.
Besides the benefits mentioned earlier, clinical trials funded by our organization adhere to the guidelines of ICH GCP and the Declaration of Helsinki, ensuring compliance with U.S. FDA regulations
The FutureMED team can further hasten clinical trial approvals in Kazakhstan due to our deep relationships with governments and institutions related to trials in the region.
For early-stage biotechs and medtechs, FutureMED provides the opportunity to run clinical trials at lower cost and shorter duration. This translates into reduced R&D risk, faster results to inform late-stage development, and greater attractiveness for investment.
Additional opportunities
TITLE 21. FOOD AND DRUGS
CHAPTER I. FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES
SUBCHAPTER D. DRUGS FOR HUMAN USE
PART 314. APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG
Subpart D - FDA Action on Applications and Abbreviated Applications
Sec. 314.106 Foreign data.
(a) General. The acceptance of foreign data in an application generally is governed by § 312.120 of this chapter.
(b) As sole basis for marketing approval. An application based solely on foreign clinical data meeting U.S. criteria for marketing approval may be approved if: (1) The foreign data are applicable to the U.S. population and U.S. medical practice; (2) the studies have been performed by clinical investigators of recognized competence; and (3) the data may be considered valid without the need for an on-site inspection by FDA or, if FDA considers such an inspection to be necessary, FDA is able to validate the data through an on-site inspection or other appropriate means.
Our partner clinics
Our partner clinics database includes more than 100 medical organizations covering a wide range
of diseases where we have deep relationships and experience in clinical trial
execution.
The majority of the healthcare facilities we collaborate with are accredited by
JCI.
Examples include:
Medical Centre Hospital of President’s Affairs Administration of The Republic of Kazakhstan
This 400-bed hospital is the leading multi-specialty institution in the country. It is accredited to Joint Commission International (JCI) standards and has a full range of modern therapeutic and diagnostic capabilities, including next-generation sequencing (NGS), robotic surgery, and nuclear medicine.
National Scientific Medical Center
The leading center for innovative medical services in Central Asia, this 240-bed hospital is included in the U.S. FDA’s database of safe clinics for conducting international clinical trials. It was named "Best Enterprise in Europe in the Field of Medicine” in 2010 by the European Business Community and the Chamber of Commerce of the European Union, and received Asian Quality Award (ANQ, Hong Kong) in 2012.
Multiple specialized clinical centers, including
Kazakh Research Institute for Oncology and Radiology ( onco.kz )
National Research Cardiac Surgery Center ( heartcenter.kz )
Research Institute for Cardiology and Internal Diseases ( ncvb.kz )
Contacts
1209 Orange Street, Wilmington, Delaware, USA, 19801
